Immunocore Holdings To Present 5-Yr OS From KIMMTRAK Phase 3 Trial In Previously Untreated HLA-A*02:01 Positive Patients With Unresected Or mUM, At 2026 AACR Annual Meeting

Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting

(OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melanoma (mUM), at the 2026 American Association for Cancer Research (AACR) Annual Meeting commencing on April 17, 2026.

The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS follow-up in a randomized trial in metastatic uveal melanoma patients. Beyond the abstract, the presentation will include additional data such as subsequent treatments in both arms, treatment beyond progression, and prognostic factors.